Search

Displaying results 5211 - 5220 of 10000 in total
  1. Drug

    Polistes metricus venom protein

    go.drugbank.com/drugs/DB11029
    Approved

    Polistes metricus venom protein is an extract of Polistes metricus venom. Polistes metricus venom protein is used in allergenic testing.

  2. Drug

    Vespula squamosa venom protein

    go.drugbank.com/drugs/DB11032
    Approved

    Vespula squamosa venom protein is an extract of Vespula squamosa venom. Vespula squamosa venom protein is used in allergenic testing.

  3. Drug

    Nilvadipine

    go.drugbank.com/drugs/DB06712
    Approved

    Nilvadipine is a calcium channel blocker (CCB) for the treatment of hypertension.

  4. Drug

    Itolizumab

    go.drugbank.com/drugs/DB16207
    Investigational

    Itolizumab is under investigation in clinical trial NCT04605926 (A Study to Evaluate the Efficacy and Safety of Itolizumab in Subjects Hospitalized With COVID-19).

  5. Drug

    Eslicarbazepine

    go.drugbank.com/drugs/DB14575
    Approved

    Eslicarbazepine is an anti-epileptic medication available commercially as [eslicarbazepine acetate].

  6. Drug

    Galidesivir

    go.drugbank.com/drugs/DB11676
    Investigational

    [A191451] In animal studies, galidesivir was effective in increasing the survival rates from infections caused by various pathogens, including Ebola, Marburg, Yellow Fever and Zika viruses. … [L12039,L12084] Phase 1 clinical trials have begun to determine the safety of this drug in humans.

  7. Drug

    MDL72527

    go.drugbank.com/drugs/DB04188
    Experimental

    Categories: Oxidoreductases Acting on CH-NH Group Donors, antagonists & inhibitors
  8. Drug

    Gemopatrilat

    go.drugbank.com/drugs/DB20954
    Experimental

    Gemopatrilat is a small molecule drug. Gemopatrilat has a monoisotopic molecular weight of 378.16 Da.

    Categories: Agents Acting on the Renin-Angiotensin System
  9. Drug

    Lufotrelvir

    go.drugbank.com/drugs/DB16514
    Investigational

    Now, it is being tested regarding the novel SARS-CoV-2 virus, including studies in conjunction with [Remdesivir] to treat COVID-19 infection; in vitro data showed synergistic effects on articles published … PF-07304814, developed by Pfizer, was first identified during the SARS outbreak in 2002-2003; it was subsequently shelved as the outbreak was controlled[L31728].

  10. Drug

    MVA3000

    go.drugbank.com/drugs/DB05040
    Experimental

    MVA3000 is an attenuated smallpox vaccine that is being developed for use in people for whom the traditional smallpox vaccine is contraindicated, such as patients with disorders of the immune system or